Pair Name | Bisdemethoxycucurmin, Icotinib | ||
Phytochemical Name | Bisdemethoxycucurmin (PubChem CID: 5315472 ) | ||
Anticancer drug Name | Icotinib (PubChem CID: 22024915 ) | ||
Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
Pair Name | Bisdemethoxycucurmin, Icotinib | |||
Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
Biological Phenomena | Induction-->Apoptosis and autophagy | |||
Gene Regulation | Down-regulation | Phosphorylation | AKT1 | hsa207 |
Up-regulation | Phosphorylation | ATM | hsa472 | |
Up-regulation | Expression | BECN1 | hsa8678 | |
Down-regulation | Expression | BIRC5 | hsa332 | |
Up-regulation | Cleavage | CASP7 | hsa840 | |
Up-regulation | Expression | CDH1 | hsa999 | |
Up-regulation | Phosphorylation | CHEK1 | hsa1111 | |
Up-regulation | Expression | CYCS | hsa54205 | |
Up-regulation | Expression | DNAJB4 | hsa11080 | |
Down-regulation | Phosphorylation | EGFR | hsa1956 | |
Down-regulation | Expression | ERBB2 | hsa2064 | |
Up-regulation | Expression | GSK3B | hsa2932 | |
Up-regulation | Expression | H2AX | hsa3014 | |
Down-regulation | Expression | HDAC1 | hsa3065 | |
Down-regulation | Expression | HDAC2 | hsa3066 | |
Down-regulation | Expression | HK1 | hsa3098 | |
Up-regulation | Expression | JUND | hsa3727 | |
Down-regulation | Expression | MAP1LC3A | hsa84557 | |
Up-regulation | Expression | MAP1LC3B | hsa81631 | |
Down-regulation | Phosphorylation | MAPK8 | hsa5599 | |
Down-regulation | Expression | MET | hsa4233 | |
Down-regulation | Expression | MMP2 | hsa4313 | |
Down-regulation | Expression | MMP9 | hsa4318 | |
Up-regulation | Cleavage | PARP1 | hsa142 | |
Down-regulation | Expression | SQSTM1 | hsa8878 | |
Up-regulation | Phosphorylation | TRIM28 | hsa10155 | |
Up-regulation | Expression | VDAC1 | hsa7416 | |
Down-regulation | Expression | VDAC2 | hsa7417 | |
Down-regulation | Expression | VEGFA | hsa7422 | |
In Vitro Model | NCI-H460 | Lung large cell carcinoma | Homo sapiens (Human) | CVCL_0459 |
NCI-H1781 | Minimally invasive lung adenocarcinoma | Homo sapiens (Human) | CVCL_1494 | |
Result | Our data indicate that BMDC has the potential to improve the treatment of primary EGFR-TKI resistant NISCLC that cannot be controlled with single-target agent, such as icotinib. |
No. | Title | Href |
---|---|---|
1 | Our data indicate that BMDC has the potential to improve the treatment of primary EGFR-TKI resistant NISCLC that cannot be controlled with single-target agent, such as icotinib. | Click |